Skip to main content

Table 4 Blood eosinophil and serum periostin levels throughout the study, by intervention

From: Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial

Day Eosinophils ×10^9/L Periostin ng/ml
FF/VI Median (min,max) Placebo Median (min,max) Point estimate of change from baseline (FF/VI – placebo) FF/VI Median (min,max) Placebo Median (min,max) Point estimate of change from baseline (FF/VI – placebo)
Pre-dose 0.35 (0.20, 1.07) 0.34 (0.18, 1.18) 191.10 (109.40, 442.50) 189.10 (99.40, 398.60)
After 14 days of treatment (day 15) 0.30 (0.18, 0.86) 0.38 (0.17, 0.99) −0.06 (− 0.14, 0.02) 150.00 (84.10, 823.40) 171.10 (87.80, 386.40) −3.56 (−44.36, 37.24)
Seven days after cessation of treatment (day 21) 0.30 (0.04, 0.85) 0.29 (0.13, 0.70) −0.02 (− 0.1, 0.08) 173.50 (94.90, 471.00) 175.70 (102.10, 389.90) −8.86 (−30.66, 12.94)
21 days after cessation of treatment (Day 35) 0.36 (0.17, 0.87) 0.40 (0.21, 1.09) −0.04 (− 0.12, 0.06) 171.70 (100.80, 457.70) 185.90 (113.30, 359.60) −5.34 (−30.16, 19.46)